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           Intrauterine growth restriction (IUGR) is gen-
erally defi  ned as fetal growth in <10th percentile 
for gestational age (  Cetin et al., 2004  ) and aff  ects 
7–15% of pregnancies (  Alexander et al., 2003  ; 
  Cetin and Alvino, 2009  ). Growth-restricted fe-
tuses have a higher incidence of mortality and 
morbidity than fetuses of normal growth, and 
are at increased risk for future development of 
metabolic disorders such as hypertension, coro-
nary heart disease, dyslipidemia, obesity, im-
paired glucose tolerance, type 2 diabetes mellitus, 
and many other diseases (  Barker, 1998  ;   Godfrey 
and Barker, 2000  ;   Baum et al., 2003  ;   Hales and 
Ozanne, 2003  ). Most cases of IUGR, particu-
larly those with signifi  cant recurrent risks, are 
often considered the result of ischemic placental 
disease (  Roberts and Post, 2008  ;   Cetin and 
Alvino, 2009  ). However, the factors contribut-
ing to placental distress and IUGR remain 
largely unknown. 
  IUGR and ischemic placentas are frequently 
associated with a serious hypertensive disorder 
of pregnancy, preeclampsia (  Kaufmann et al., 
2003  ). When IUGR is observed, the preeclamp-
tic mothers often have a poorly developed 
placenta characterized by shallow trophoblast 
invasion and inadequate spiral artery remodeling 
(  Zhou et al., 1997a  ;   Zhou et al., 1997b  ). There-
fore, preeclampsia represents an appropriate dis-
ease model to investigate the molecular basis of 
placental damage and IUGR. Alterations in both 
the immune system and the renin–angiotensin 
system (RAS) are believed to contribute to the 
pathophysiology of preeclampsia (  Redman and 
Sargent, 2005  ;   Shah, 2006  ;   Saito et al., 2007  , 
  Irani and Xia, 2008  ). Recently, these two mech-
anisms have been merged with reports that pre-
eclamptic women harbor autoantibodies that 
activate the major angiotensin II (Ang II) receptor, 
CORRESPONDENCE  
 Yang  Xia: 
yang.xia@uth.tmc.edu
  Abbreviations used: Ang II, 
angiotensin II; AT  1  -AA, AT  1   
receptor agonistic autoantibody; 
CHO, Chinese hamster ovary; 
IUGR, intrauterine growth 
restriction; TUNEL, terminal 
deoxynucleotidyl transferase–
mediated dUTP nick-end 
labeling.   
  The detrimental role of angiotensin receptor 
agonistic autoantibodies in intrauterine 
growth restriction seen in preeclampsia 
    Roxanna A.     Irani  ,    1      Yujin     Zhang  ,    1       Sean C.     Blackwell  ,    2       Cissy Chenyi     Zhou  ,    1     
  Susan M.     Ramin  ,    2       Rodney E.     Kellems  ,    1     and   Yang     Xia      1     
  1  Department of Biochemistry and Molecular Biology and   2  Department of Obstetrics, Gynecology, and Reproductive Sciences, 
University of Texas Medical School at Houston, Houston, TX, 77030     
  Growth-restricted fetuses are at risk for a variety of lifelong medical conditions. Pre-
eclampsia, a life-threatening hypertensive disorder of pregnancy, is associated with fetuses 
who suffer from intrauterine growth restriction (IUGR). Recently, emerging evidence indi-
cates that preeclamptic women harbor AT  1   receptor agonistic autoantibodies (AT  1  -AAs) 
that contribute to the disease features. However, the exact role of AT  1  -AAs in IUGR and 
the underlying mechanisms have not been identifi  ed. We report that these autoantibodies 
are present in the cord blood of women with preeclampsia and retain the ability to acti-
vate AT  1   receptors. Using an autoantibody-induced animal model of preeclampsia, we show 
that AT  1  -AAs cross the mouse placenta, enter fetal circulation, and lead to small fetuses 
with organ growth retardation. AT  1  -AAs also induce apoptosis in the placentas of pregnant 
mice, human villous explants, and human trophoblast cells. Finally, autoantibody-induced 
IUGR and placental apoptosis are diminished by either losartan or an autoantibody-
neutralizing peptide. Thus, these studies identify AT  1  -AA as a novel causative factor of 
preeclampsia-associated IUGR and offer two possible underlying mechanisms: a direct 
detrimental effect on fetal development by crossing the placenta and entering fetal circu-
lation, and indirectly through AT  1  -AA–induced placental damage. Our fi  ndings highlight 
AT  1  -AAs as important therapeutic targets. 
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that is easily obtained at the time of parturition. To determine 
if AT  1  -AAs cross from the maternal to fetal circulation during 
pregnancy, we obtained maternal and cord blood from nor-
motensive pregnant women and women with preeclampsia. 
Total IgG was isolated from serum and examined for the pres-
ence of AT  1  -AAs. The results of the Western blot (  Fig. 1 A  ) 
show that total IgGs from maternal and cord sera of women 
with preeclampsia detected a band of 43 kD, corresponding to 
the AT  1   receptor derived from cellular lysates enriched with 
the receptor that were transferred to a nitrocellulose membrane.  
In contrast, IgG from maternal and cord sera of women with 
normotensive pregnancies did not cross react with a protein 
of 43 kD (  Fig. 1 A  ). To further confi  rm this result, an affi   n-
ity chromatography strategy was used to specifi  cally isolate 
AT  1  -AAs from the cord blood of fetuses from women with 
preeclampsia. The Western blot indicates that only the eluted 
fraction (AT  1  -AAs) could detect a band at 43 kD, correspond-
ing to the AT  1   receptor, whereas the fl  ow-through fraction 
did not. These fi  ndings suggest that specifi  c IgGs from women 
with preeclampsia that bind to the AT  1   receptor can cross the 
placenta and enter the fetal circulation. 
  To determine if the IgGs that enter the fetal circulation 
retain the ability to activate AT  1   receptors, we incubated 
IgGs from cord blood with a reporter cell line in which AT  1   
receptor activation results in increased expression of a lucifer-
ase reporter gene. The results (  Fig. 1 B  ) showed that lucifer-
ase activity was stimulated only when using IgG isolated from 
preeclamptic cord blood and that this activity was blocked by 
the presence of 100 nM losartan, an AT  1   receptor antagonist. 
The activity was also inhibited by a 7-aa peptide that corre-
sponds to an epitope on the second extracellular loop of 
the AT  1   receptor that is recognized by autoantibodies from 
women with preeclampsia (  Fig. 1 B  ). Similarly in the AT  1  -AA 
affi   nity purifi  cation experiment, only the eluted fraction of 
IgGs from the cord blood of babies born to preeclamptic 
women stimulated luciferase activity, whereas the fl  ow-through 
fraction was unable to do so. Collectively, these fi  ndings 
demonstrated that AT  1  -AAs from the maternal circulation 
cross the placenta and enter fetal circulation, where they re-
tain the ability to activate AT  1   receptors. 
  Human AT  1  -AAs can cross the mouse placenta 
and enter fetal mouse circulation 
  To determine if AT  1  -AAs can cross the mouse placenta and 
enter fetal circulation, we took advantage of the autoantibody-
injected model of preeclampsia. Specifi  cally, pregnant mice 
were injected with total IgG from normotensive pregnant 
women or from women with preeclampsia on embryonic 
day (E) 13 and E14. Blood was obtained from the dams and 
their fetuses upon sacrifi  ce on E18 and examined for the 
presence of human IgG using Western blotting and ELISA. 
The results (  Fig. 2, A and B  ) showed that similar amounts 
of human IgG were present in the maternal and fetal sera of 
antibody-injected pregnant mice.   To determine if the pre-
eclamptic IgG retained AT  1   receptor agonistic activity after 
crossing the mouse placenta and entering fetal circulation, 
AT  1  , and are hence termed AT  1   receptor agonistic autoanti-
bodies (AT  1  -AAs;   Wallukat et al., 1999  ). Many features of 
preeclampsia can be explained by the ability of these autoanti-
bodies to activate AT  1   receptor on a variety of cell types (  Xia 
et al., 2003  ;   Thway et al., 2004  ;   Bobst et al., 2005  ;   Zhou 
et al., 2008a  ). We have recently shown that the introduction 
of these autoantibodies into pregnant mice resulted in hyper-
tension, proteinuria, and other key features of preeclampsia 
(  Zhou et al., 2008b  ). The autoantibody-induced features of 
preeclampsia were prevented by coinjection with losartan, an 
AT  1   receptor antagonist, or a 7-aa epitope peptide that blocks 
autoantibody-induced AT  1   receptor activation. These in vivo 
studies provide the fi  rst direct evidence of the pathophysio-
logical role of AT  1  -AAs in the maternal features of preeclamp-
sia, and suggest that this animal model will be an extremely 
valuable investigative tool to analyze the underlying patho-
genic mechanisms of various abnormalities associated with the 
disease. Thus, we used this animal model of preeclampsia to 
address the exact contributory role of AT  1  -AAs in IUGR and 
its underlying mechanisms. 
  In this paper, we show that AT  1  -AAs exist in the cord 
blood of women with preeclampsia and in the fetal circula-
tion of autoantibody-injected pregnant mice. We also ob-
served that the autoantibody-induced preeclamptic model 
results in IUGR with impaired multiple organ development. 
Our fi  ndings indicate that these pathogenic autoantibodies 
enter the fetal circulation, where they may have a direct det-
rimental eff  ect on fetal growth and maturation. Additionally, 
we found that AT  1  -AAs impair placental development, re-
sulting in organs characterized by increased apoptosis. These 
results were corroborated with similar fi  ndings in human 
placental villous explants and in cultured human trophoblast 
cells exposed to the autoantibody. These studies demonstrate 
that an abnormal placenta may be another underlying mech-
anism for AT  1  -AA–induced IUGR. Finally, autoantibody-
induced fetal growth restriction and placental apoptosis were 
largely corrected by coinjection with either losartan or an 
antibody-neutralizing 7-aa epitope peptide, indicating that 
autoantibody-mediated AT  1   receptor activation was required. 
Overall, our studies reveal the detrimental role of AT  1  -AAs 
in IUGR and reveal two underlying mechanisms for this 
process. These novel fi  ndings point to possible adverse eff  ects 
of AT  1  -AAs on babies born to mothers with preeclampsia 
and identify these autoantibodies as potentially important 
therapeutic targets. 
  RESULTS 
  Autoantibodies from preeclamptic women are present 
in cord blood and retain the ability to activate AT  1   receptors 
  The placenta is a massive vascular organ that brings maternal 
and fetal circulatory systems into close proximity, facilitating 
the nutrient and gas exchange essential for fetal development 
(  Georgiades et al., 2002  ). Maternal blood is supplied to the 
placenta via the uterine spiral arteries, and the fetus receives 
blood from the vessels present in the umbilical cord. Cord 
blood therefore represents a convenient source of fetal blood JEM VOL. 206, November 23, 2009 
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human IgG isolated from mouse fetal circulation was assayed 
for its ability to activate AT  1   receptors using a reporter cell 
line in which AT  1   receptor activation results in the activation 
of an NFAT-luciferase reporter gene. The results (  Fig. 2 C  ) 
showed that IgG from the fetal blood of pregnant mice in-
jected with preeclamptic IgG retained AT  1   receptor agonistic 
activity. However, the fetuses of dams injected with IgG de-
rived from normotensive patients harbored IgG that could 
not stimulate luciferase activity (  Fig. 2 C  ). These data indi-
cate that human AT  1  -AAs from women with preeclampsia 
cross the mouse placenta and enter fetal mouse circulation, 
where they retain the ability to activate AT  1   receptors. 
  Injection of affi  nity-purifi  ed AT  1  -AAs into pregnant mice 
results in small fetuses and adversely affects kidney 
and liver development 
  Because of the process of passive immunity between mother 
and developing child, the potentially harmful autoantibodies as-
sociated with preeclampsia may enter fetal circulation and have 
a direct detrimental eff  ect on the growing fetus. To investigate 
this possibility, affi   nity-purifi  ed AT  1  -AAs were injected into 
pregnant mice on E13 and E14, and the injected mice were 
examined 5 d later for the clinical signs of preeclampsia and 
their fetuses were examined for abnormalities of growth. The 
results (  Fig. 3  ) show that autoantibody-injected mice bore fe-
tuses of reduced weight (1.01 ± 0.02 g) as compared with dams 
injected with normotensive IgG (1.17 ± 0.02 g).   Coinjecting 
AT  1  -AAs with either losartan or 7-aa epitope peptide restored 
fetal size to 1.119 ± 0.01 g and 1.151 ± 0.04 g, respectively. 
Furthermore, the fetuses exhibited renal and hepatic develop-
mental delays. Histological analysis of fetal kidneys showed that 
the zone of nephrogenesis was narrowed and the number of 
glomeruli was decreased in the kidneys of fetuses born to mice 
injected with affi   nity-purifi  ed AT  1  -AAs (  Fig. 3, B–D  ). These 
fi  ndings suggest that the renal development of these fetuses had 
been retarded (  Alexander, 2003  ). Similarly, the livers of fetuses 
born to dams injected with AT  1  -AAs show developmental im-
pediment. During normal mouse development, the fetal liver 
is the major site of embryonic blood production. From E10 
to birth, the number of megakaryocyte progenitors begins to 
decrease with advancing gestational age (  Matsumura and 
Sasaki, 1989  ). Our histological results showed that the injection 
of affi   nity-purifi  ed AT  1  -AAs from women with preeclampsia 
into pregnant mice is associated with a consistently elevated 
number of megakaryocytes in the fetal mouse liver (  Fig. 3, 
E and F  ). This persistence of megakaryocytes suggests a delay 
in normal organ maturation. Thus, the autoantibody injection 
model of preeclampsia in pregnant mice has provided in vivo 
evidence that AT  1  -AAs can adversely aff  ect fetal growth and 
organ development. Notably, both human and mouse stud-
ies indicate that AT  1  -AAs pass through the placenta and enter 
fetal circulation, where they retain biological activity. These 
fi  ndings reveal a previously unrecognized possible underlying 
mechanism of AT  1  -AA–induced IUGR: that the autoanti-
body may have direct detrimental eff  ects on fetal development 
by crossing the placenta and entering fetal circulation. 
    Figure 1.     AT  1  -AAs can pass through the human placenta and retain 
biological activity in fetal circulation.   (A and B) Autoantibodies detected 
by Western blot in the sera of preeclamptic women could also be found in 
cord blood (A). Cellular lysate from CHO.AT1A cells containing stably inte-
grated copies of a minigene encoding the AT  1   receptor was run on a 10% 
SDS-PAGE gel and transferred to a nitrocellulose membrane. The AT  1   recep-
tor–rich membrane was cut into strips and each strip was individually 
probed by either an anti–AT  1   receptor antibody (control), or purifi  ed anti-
bodies derived from maternal serum or cord blood from normotensive (  n   =  6) 
or preeclamptic (  n   = 6) pregnancies. Also, to specifi  cally detect AT  1 -AAs 
from the total IgG pool, an affi  nity purifi  cation strategy was used. The 
fl  ow-through and eluted affi  nity-purifi  ed fractions of IgGs derived from 
the cord blood of babies from preeclamptic patients were also tested for 
their ability to bind to the AT  1   receptor  ( n   = 6). Only preeclamptic maternal 
sera, cord blood from babies of preeclamptic women, and the eluted affi  nity-
purifi  ed fraction harbored autoantibodies recognizing the AT  1   receptor  at 
43 kD. Then, cord blood IgGs were tested for biological activity (B) using an 
in vitro luciferase activity assay that is increased secondary to AT  1   receptor 
activation. Only IgGs purifi  ed from the cord blood of babies from pre-
eclamptic patients or the eluted affi  nity-purifi  ed fraction induced luciferase 
activity. This bioactivity could be blocked by co-culturing the reporter cell 
line with IgG derived from preeclamptic patients and losartan or the 7-aa 
epitope peptide (  n   = 5 for each variable in two independent experiments). 
Data are expressed as means ± SEM. *, P < 0.01 versus IgG derived from 
cord blood of a normotensive patient; **, P < 0.01 versus IgG derived from 
cord blood of a preeclamptic patient; +, P < 0.01 versus fl  ow-through 
affi  nity-purifi  ed fraction. NT, normotensive; PE, preeclampsia.     2812 AT  1  -AA in IUGR   | Irani et al. 
we evaluated the size and morphology of placentas in the 
autoantibody-injected mouse model of preeclampsia. The re-
sults (  Fig. 3  ) show that placentas from pregnant mice injected 
with AT  1  -AAs were signifi  cantly smaller (0.0939 ± 0.008 g) 
than placentas from mice injected with a comparable amount 
of total IgG from normotensive pregnant women (0.1039 ± 
0.014 g). In addition, coinjection of AT  1  -AAs with either 
losartan or 7-aa epitope peptide restored placental size to 
0.0991 ± 0.009 g and 0.105 ± 0.023 g, respectively. To de-
termine whether increased apoptosis is a potential cause of 
the small placentas observed in AT  1  -AA–injected pregnant 
mice, we performed terminal deoxynucleotidyl transferase–
mediated dUTP nick-end labeling (TUNEL) staining for 
apoptotic cells and found that the reduction in placental size 
was accompanied by an increase in apoptosis evident in the 
labyrinth zone of placentas from mice injected with AT  1  -AAs 
(  Fig. 4, A and B  ).   In addition, Bax, a proapoptotic marker, 
was increased, and Bcl-2, an antiapoptotic marker, was de-
creased as determined by Western blot analysis of mouse 
placenta protein extracts (  Fig. 4, C and D  ). Coinjection of 
AT  1  -AAs with losartan or 7-aa epitope peptide signifi  cantly 
inhibited these features. Therefore, increased apoptosis may 
contribute to the reduction in placental size in pregnant mice 
injected with AT  1  -AAs. These findings also suggest that 
an impaired placenta may indirectly be another underlying 
mechanism of AT  1  -AA–induced IUGR in pregnant mice. 
  To evaluate the pathophysiologic signifi  cance of the role 
of AT  1  -AAs in impaired placental development in preeclamp-
sia, human placenta villous explants from healthy term preg-
nancies were incubated with IgG from normotensive pregnant 
women or IgG from women with preeclampsia. After incu-
bation with the Igs, placental villous explants were embedded 
and sectioned to perform TUNEL staining. The results (  Fig. 5, 
A and B  ) show that the presence of IgGs from women with 
preeclampsia increased apoptosis in these explants.   The auto-
antibody-induced increase in apoptosis was inhibited by 
coincubation with losartan or the 7-aa epitope peptide. The 
histological evidence for apoptosis was corroborated with 
Western blot analysis indicating an increase in Bax and a de-
crease in Bcl-2 proteins, resulting in a proapoptotic state in 
these explants (  Fig. 5, C and D  ). Similarly, cotreatment with 
losartan or the 7-aa neutralizing epitope peptide partially abol-
ished the alterations in Bax and Bcl-2 proteins induced by these 
autoantibodies. These studies demonstrate that AT  1  -AAs are 
capable of inducing apoptosis in human placenta explants 
through AT  1   receptor activation and may potentially con-
tribute to IUGR via this mechanism in humans. 
  AT  1   receptor activation induces apoptosis 
in human trophoblast cells 
  Many studies report that human trophoblast cells house the 
full machinery for apoptotic cell death (  Allaire et al., 2000  ; 
  Huppertz et al., 2006  ;   Kadyrov et al., 2006  ). They also pos-
sess the AT  1   receptor (  Li et al., 1998  ;   Xia et al., 2002  ). To 
further elucidate the mechanism by which cell death may oc-
cur in the placenta of a preeclamptic woman, we monitored 
  AT  1  -AA–increased placental apoptosis in pregnant mice 
and human villous explants 
  Placental health is vital for normal fetal development. In an 
eff  ort to determine whether an impaired placenta is another 
potential underlying mechanism for AT  1  -AA–induced IUGR, 
    Figure 2.     Human IgG crosses the mouse placenta and can be de-
tected in fetal mouse sera where it retains biological activity.  
(A–C) Human IgG could be detected in fetal mouse circulation by Western 
blotting (A) and ELISA (B). IgGs from normotensive or preeclamptic preg-
nant women were injected into pregnant mice at E13 and E14. Fetal sera 
were collected upon sacrifi  ce on E18. Human IgG was detected in fetal 
mouse circulation (born to dams injected with human IgG) by Western 
blotting (A) using an anti–human IgG antibody, but not in the circulation 
of mice born to dams without human IgG injection. The concentration of 
human IgG in fetal mouse circulation was detected by an ELISA specifi  c 
for human IgG (B). IgGs from both normotensive and preeclamptic preg-
nancies were detectable in fetal mice circulation, and the level of IgGs in 
fetal circulation between the two injected groups (  n   = 7 for each group in 
three independent experiments) was not signifi  cantly different (P > 0.05). 
However, the only group whose serum harbored antibodies that recog-
nized the AT  1   receptor and maintained the biological activity was the 
fetuses of preeclamptic IgG-injected mice (C). This was assessed by using 
a bioassay wherein AT  1   receptor activation induces luciferase activity in 
transfected CHO-NFAT cells (  n   = 5 for each variable in two independent 
experiments). Data are expressed as means ± SEM. *, P < 0.01 versus nor-
motensive IgG treatment; **, P < 0.01 versus preeclamptic IgG treatment. 
NT, normotensive; PE, preeclampsia.     JEM VOL. 206, November 23, 2009 
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    Figure 3.     AT  1   receptor activation results in decreased fetal weight and impaired organ development.   AT 1   receptor activation results in fetal ab-
normalities. (A) Injection of pregnant mice with IgGs from preeclamptic women resulted in fetuses weighing less than those born to pregnant mice in-
jected with IgG derived from normotensive women. Only pups born in litters of six to eight were analyzed, and those depicted in the fi  gure were selected 
from the center of the uterine horn (preeclamptic fetuses,   n   = 89; and normotensive fetuses,   n   = 80, collected and analyzed in four independent experi-
ments). *, P < 0.05 versus normotensive IgG treatment. (B) Fetal mouse kidney histology (H&E staining). Bars, 50 μm. (C and D) As compared with the fetal 
kidneys from normotensive IgG injection litters, the kidneys from litters of preeclamptic IgG injection dams demonstrated a narrow nephrogenic zone 
(C) and a decreased number of glomeruli (D). The double arrows in B demarcate the nephrogenic zone. Arrowheads within the boxes indicate a glomerulus 
within a representative high power fi  eld. (E) Fetal mouse liver histology (H&E staining). Bars, 50 μm. (F) Compared with the livers of pups born to dams 
injected with normotensive IgG, the livers from pups of preeclamptic IgG injection dams showed an increased number of megakaryocytes. Arrows indicate 
megakaryocytes. When losartan (PE + Losartan) or the 7-aa peptide (PE + 7-aa) were coinjected into the dams, the fetal kidney and liver alterations were 
partially abolished (  n   = 12 for each variable for the histological analysis in four independent experiments). Data are expressed as means ± SEM. *, P < 0.05 
versus normotensive IgG treatment; **, P < 0.05 versus preeclamptic IgG treatment. hpf, high power fi  eld; NT, normotensive; PE, preeclampsia.     2814 AT  1  -AA in IUGR   | Irani et al. 
apoptosis in trophoblast cells. Consistent with the fi  ndings 
in mouse placental sections and human placental villous ex-
plants, we found that the increased apoptosis in the human 
trophoblast cells by AT  1  -AAs was inhibited by coincubation 
with losartan or the 7-aa epitope peptide (  Fig. 6, A and B  ). In 
addition, the activity of caspase 3, a rapidly activated cysteine 
protease essential for cell death, was measured in the cultured 
trophoblast cells to corroborate the TUNEL assay results. 
HTR-8/SVneo cells incubated with IgG from preeclamptic 
the levels of apoptosis in trophoblasts after stimulation with 
IgG purifi  ed from preeclamptic or normotensive pregnant 
individuals. Interestingly, IgG purifi  ed from preeclamptic in-
dividuals induced an increase in programmed cell death in an 
immortalized human trophoblast line, HTR-8/SVneo (  Fig. 6, 
A and B  ).   This is in contrast to IgG from normotensive preg-
nant women, which did not raise the level of apoptosis as as-
sessed by a TUNEL assay and apoptotic index. These fi  ndings 
reveal that AT  1   receptor activation is capable of inducing 
    Figure 4.     Mouse placentas demonstrate increased apoptosis caused by AT  1   receptor activation.   The placentas of AT  1 -AA–injected  pregnant 
mice have increased apoptosis. (A) TUNEL-stained mouse placental sections demonstrate increased apoptosis in the labyrinth zone of mice injected with 
IgG from preeclamptic women as compared with normotensive IgG-injected mice (green, TUNEL  +  ; blue, DAPI nuclear stain). Bars, 500 μm. (B) This quali-
tative increase in apoptosis is quantifi  ed and corroborated with an increased apoptotic index (percentage of TUNEL-/DAPI-positive cells) as measured in 
the same mouse placental sections (  n   = 12 placentas for each variable collected over four independent experiments). (C and D) Western blot analysis of 
mouse placentas indicates that AT  1   receptor activation leads to increased Bax (C) and decreased Bcl-2 (D;   n   = 6 for each variable collected over four 
independent experiments). Mice coinjected with IgG from preeclamptic women and either losartan or 7-aa epitope peptide have placentas that demon-
strate less apoptotic features. Data are expressed as means ± SEM. *, P < 0.05 versus normotensive IgG treatment; **, P < 0.05 versus preeclamptic IgG 
treatment. NT, normotensive; PE, preeclampsia.     JEM VOL. 206, November 23, 2009 
Article
2815
villous explants that demonstrate increased apoptosis when 
exposed to the autoantibody (  Fig. 5  ). Overall, these results 
provide strong in vitro evidence that autoantibodies isolated 
from the sera of preeclamptic women are capable of activat-
ing AT  1   receptors on human trophoblast cells and inducing 
their programmed cell death. 
women exhibited a higher caspase 3 activity level over those 
incubated with IgG isolated from normotensive pregnant 
women (  Fig. 6 C  ). The coincubation of the cultured tropho-
blast cells with AT  1  -AAs and losartan or the 7-aa epitope 
peptide reduced the caspase 3 activity signifi  cantly. These 
data support the fi  ndings obtained from the human placental 
    Figure 5.     Human villous explants exhibit increased apoptosis caused by AT  1   receptor activation.   AT 1   receptor activation induces human pla-
cental apoptosis. (A) Human villous explants cultured with IgG derived from preeclamptic patients demonstrate increased apoptosis as compared with 
explants incubated with IgG derived from normotensive sera. TUNEL-stained cultured human villous explants indicate that AT  1  -AAs, through AT  1 -
receptor activation, increase apoptosis (green, TUNEL  +  ; blue, DAPI nuclear stain). Bars, 500 μm. (B) Quantifi  cation of the increased apoptosis is refl  ected 
in an increased apoptotic index in the explants incubated with PE IgG (B). (C and D) Western blot analysis of explant proteins demonstrate increased 
Bax (C) and decreased Bcl-2 (D), indicating a proapoptotic state. Coincubation of the explants with preeclamptic IgG and losartan or 7-aa epitope pep-
tide partially attenuated the increase in cell death. Explants of placentas from four different patients were cultured, and each variable was examined 
six times per placenta (  n   = 24). Data are expressed as means ± SEM. *, P < 0.05 versus normotensive IgG treatment; **, P < 0.05 versus preeclamptic 
IgG treatment. NT, normotensive; PE, preeclampsia.     2816 AT  1  -AA in IUGR   | Irani et al. 
AT  1   receptor activation may be a novel eff  ective therapy for 
treating the IUGR associated with preeclampsia. 
  Although losartan is contraindicated during early pregnancy 
because of its fetotoxic eff  ects (  Spence et al., 1995  ;   Saji et al., 
2001  ), drugs aimed at neutralizing the effects of AT  1  -AAs 
would not be expected to have harmful eff  ects on the devel-
oping fetus. Because the 7-aa neutralizing peptide blocked 
the apoptosis induced by AT  1  -AAs in cultured human villous 
explants (  Fig. 5  ), we speculated that the epitope peptide may 
be eff  ective in blocking the placental apoptosis and IUGR 
seen in AT  1  -AA–injected pregnant mice. For this reason, we 
conducted experiments in which pregnant mice were coin-
jected with AT  1  -AAs and excess 7-aa epitope peptide on E13 
and E14 to block the ability of the autoantibody to activate 
AT  1   receptors. 5 d later, on E18, pregnant mice were sacri-
fi  ced and their pups and placentas were collected. The results 
show that the 7-aa epitope peptide blocked placental apop-
tosis and alterations of apoptotic proteins, and small fetuses 
  Inhibition of AT  1   receptor activation or neutralization 
of AT  1  -AAs reduced the IUGR and placental 
apoptosis seen in autoantibody-injected pregnant mice: 
a novel therapeutic strategy 
  Lastly, to determine the direct pathogenic role of AT  1  -AAs 
and the benefi  t of inhibiting AT  1   receptor activation in IUGR, 
we coinjected losartan, a specifi  c AT  1   receptor antagonist, with 
AT  1  -AAs into pregnant mice at E13 and E14. We found that 
the coinjection of losartan attenuated the reduced placental 
size associated with autoantibody-induced placental apoptosis 
and the increased expression of Bax and the decreased expres-
sion of Bcl-2 (  Fig. 4  ). At the same time, the coinjection of 
AT  1  -AAs and losartan into pregnant mice also ameliorated the 
reduction in fetal size and developmental impairment of fetal 
kidneys and liver (  Fig. 3  ). Collectively, these results demon-
strate that impaired fetal growth and increased placental apop-
tosis were mediated by autoantibody-induced AT  1   receptor 
activation and suggest that blocking autoantibody-mediated 
    Figure 6.     AT  1   receptor activation increases trophoblast cell apoptosis.   AT 1   receptor activation induces apoptosis in HTR-8/SVneo cells, a human tro-
phoblast cell line. (A–C) HTR-8/SVneo cells cultured with IgG derived from preeclamptic patients demonstrate increased apoptosis as compared with ex-
plants incubated with IgG derived from normotensive sera. A cell death index (A) based on TUNEL-stained HTR-8/SVneo cells (B) indicates that AT  1   receptor 
activation increases apoptosis. Caspase 3 activity (C) is also increased in HTR-8/SVneo cells cultured with IgG from preeclamptic patients as compared with 
those cultured with IgG from normotensive patients. Coincubation of PE IgG with losartan or 7-aa epitope peptide reduces the amount of apoptosis as well 
as caspase 3 activity (green, TUNEL  +  ; blue, DAPI nuclear stain;   n   = 12 for each variable in three independent experiments). Data are expressed as means ± 
SEM. *, P < 0.05 versus normotensive IgG treatment; **, P < 0.05 versus preeclamptic IgG treatment. NT, normotensive; PE, preeclampsia. Bars, 500 μm.     JEM VOL. 206, November 23, 2009 
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  In this paper, we have shown that AT  1  -AAs induce apop-
tosis in cultured human trophoblast cells, in human villous ex-
plants, and in the placentas of autoantibody-injected pregnant 
mice. Thus, the impaired placenta is likely another underlying 
mechanism responsible for AT  1  -AA–induced IUGR. In both 
the cardiac and renal systems, Ang II has been shown to 
increase cell death through various proapoptotic pathways 
(  Ruiz-Ortega et al., 1998  ;   Kalra et al., 2002  ). In addition, tro-
phoblasts house the AT  1   receptor as well as all the machinery 
necessary to undergo apoptosis (  DiFederico et al., 1999  ; 
  Huppertz et al., 2006  ). Therefore, it was not unexpected that 
AT  1  -AAs were capable of inducing trophoblast cell death via 
AT  1   receptor activation. Poor placental development is associ-
ated with a proapoptotic placental environment that includes 
increased production of Bax and decreased production of 
Bcl-2 (  Huppertz and Kingdom, 2004  ). These features con-
tribute to a suboptimal environment for placental develop-
ment and result in an impaired placenta. Autoantibody-induced 
AT  1   receptor activation may contribute to impaired placental 
development in other ways, such as decreased angiogenesis 
(  Zhou et al., 2007  ), decreased trophoblast invasion (  Xia et al., 
2003  ), increased production of reactive oxygen species ( Sedeek 
et al., 2003  ;   Sedeek et al., 2008  ), and increased thrombosis 
(  Shaarawy and Didy, 1996  ;   Bobst et al., 2005  ). These reports 
are in agreement with double-transgenic mouse studies that 
show that increased placental renin production leads to in-
creased Ang II in the maternal circulation and results in im-
paired, highly apoptotic placentas and pups suff  ering  from 
IUGR (  Takimoto et al., 1996  ;   Saito et al., 2004  ). Although 
preeclampsia in humans is not associated with increased Ang II 
levels (  Langer et al., 1998  ), as in this double-transgenic mouse 
model, human preeclampsia is associated with the presence of 
autoantibodies, AT  1  -AAs, that mimic the physiological action 
of Ang II (  Wallukat et al., 1999  ). Therefore, the additive ac-
tions of Ang II and AT  1  -AAs may result in elevated AT  1   re-
ceptor activation and could contribute to impaired placental 
development and IUGR. This concept is supported by the 
observations reported in this paper and suggest that autoanti-
body-induced AT  1   receptor activation likely contributes to 
impaired placental development and is an underlying mecha-
nism for the IUGR observed in preeclampsia. 
  AT  1   receptor activation is also related to another factor 
associated with the small placentas and IUGR of severe pre-
eclampsia: reduced aa transport. 20–40% of the energy 
needed for fetal growth is supplied from aa’s found in the 
maternal circulation (  Bauer et al., 1998  ). If the aa transporter 
systems of the placenta are impaired, the developing fetus is 
nutritionally starved and is at risk for growth defects. Nu-
merous aa transport systems are Na  +   dependent and couple 
the uptake of aa’s with that of Na  +   into the cell. The Na  +  -K  +  -
ATPase is highly abundant in most cell types, including pla-
cental syncytiotrophoblasts (  Johansson et al., 2000  ), where 
they maintain a low intracellular Na  +   concentration by 
transporting Na  +   outside the cells and provide a Na  +   gradi-
ent, the essential driving force for Na  +  -dependent aa trans-
port systems. Recent studies have not only shown that the 
with impaired organ development (  Fig. 3  ). The neutraliz-
ing eff  ects of losartan and 7-aa epitope peptide indicate that 
AT  1  -AAs contribute to the IUGR associated with preeclampsia 
and suggest that blockade of the detrimental autoantibody 
eff  ects may yield a novel therapeutic strategy for this life-
threatening disease. 
  DISCUSSION 
  In this study, we discovered that biologically active autoanti-
bodies cross the placenta and enter fetal circulation in pre-
eclamptic patients. We used an autoantibody injection mouse 
model of preeclampsia to identify the detrimental role of 
AT  1  -AAs in IUGR. We show that these autoantibodies may 
contribute to fetal growth restriction via two previously un-
recognized mechanisms: (a) directly, by crossing the mouse 
placenta and entering fetal mouse circulation as we see in 
humans, and (b) indirectly, via AT  1  -AA–induced placental 
impairment characterized by increased apoptosis. Finally, 
autoantibody-induced fetal growth restriction and placental 
apoptosis were largely corrected by either losartan or an anti-
body-neutralizing 7-aa epitope peptide, indicating that auto-
antibody-induced AT  1   receptor activation was required. 
Thus, our studies reveal the detrimental role of AT  1  -AAs in 
preeclampsia-associated IUGR, off  er underlying mechanisms 
for this process, and suggest a novel therapeutic strategy based 
on these autoantibody-induced mechanisms. 
  During the third trimester of pregnancy, antibodies gener-
ated by the mother cross the placenta and enter fetal circula-
tion. The transfer of Ig from mother to fetus is a naturally 
occurring process by which the mother confers immunity to 
the developing fetus. This process of passive immunity puts 
the growing fetus at risk if the mother carries autoantibodies 
that are harmful. A well-known example of this is Graves’ 
disease, where maternal autoantibodies that activate the 
thyroid-stimulating hormone receptor pass through the pla-
centa, enter the fetal circulation, and cause hyperthyroidism in 
the fetus and newborn (  Chistiakov, 2003  ). Other autoimmune 
diseases, such as systemic lupus erythematosus, Sjögren’s syn-
drome, and antiphospholipid syndrome, are associated with 
the pathogenic autoantibodies that result in severe complica-
tions of pregnancy, often resulting in severe IUGR and fetal 
loss (  Siamopoulou-Mavridou et al., 1988  ;   Deleze et al., 1989  ; 
  Julkunen et al., 1995  ;   Holers et al., 2002  ). Because preeclamp-
sia is also associated with the presence of pathogenic autoanti-
bodies (i.e., AT  1  -AAs) in the maternal circulation, it is possible 
that these autoantibodies may be transferred to the fetus and 
cause harm. Using an autoantibody injection model of pre-
eclampsia in the pregnant mouse, we have shown in this study 
that AT  1  -AAs are transported from the maternal circulation 
through the placenta into the fetal circulation, where they can 
be physically and biologically detected. The research reported 
in this paper shows that the presence of these autoantibodies 
in the fetal mouse circulation is associated with smaller fetuses 
who suff  er from renal and liver abnormalities. Thus, these au-
toantibodies may also have direct detrimental eff  ects on the 
fetuses of women with preeclampsia. 2818 AT  1  -AA in IUGR   | Irani et al. 
thrombosis and recurrent fetal loss (  Salmon and Girardi, 
2008  ). It is reported that recurrent fetal loss occurs in     1% 
of pregnant women and that up to 20% of these women 
have antiphospholipid antibodies (  Girardi et al., 2003  ). Us-
ing an antibody injection model of fetal loss in pregnant 
mice, Girardi et al. have shown that these autoantibodies are 
directed at targets in the decidua and lead to the activation 
of complement, the recruitment of neutrophils, and the 
enhanced production of tissue factor, TNF, antiangiogenic 
factors, and reactive oxygen species, all of which lead to fe-
tal loss (  Redecha et al., 2007  ). It is interesting to note that 
these same features are also induced by AT  1  -AAs in a variety 
of systems (  Sedeek et al., 2003  ;   Zhou et al., 2007  ;   Sedeek 
et al., 2008  ). Thus, these autoantibody-induced models of 
IUGR including fetal loss (perhaps resulting from a severe 
impairment of placental development) have shown that 
immunological factors, including components of the innate 
and adaptive arms of the immune system, contribute to preg-
nancy loss and IUGR. In each case, the sequence of events 
leading to IUGR is initiated by a maternal autoantibody. 
Together, AT  1  -AAs and antiphospholipid antibodies may 
account for one third of the cases of IUGR and pregnancy 
loss (  Holers et al., 2002  ). The role of autoantibodies in other 
cases of IUGR, impaired placental development, and/or fetal 
loss warrants further investigation. 
Na  +  -K  +  -ATPase is down-regulated in cases of IUGR 
(  Johansson et al., 2003  ) but that the inhibitory eff  ect on Na  +  -
dependent aa transport systems may be through AT  1   recep-
tor signaling. Of particular interest is a study by   Shibata et al.   
(  2006  ) that reports that Ang II inhibits system A aa trans-
porter activity in human placental villous fragments through 
AT  1   receptor activation. The system A aa transporter is a 
Na  +  -dependent aa transporter that mediates transport of the 
small neutral aa’s alanine, serine, glutamine, and glycine by 
human syncytiotrophoblasts. The authors show that Ang II, 
via AT  1   receptor signaling, decreases system A activity by 
suppressing Na  +  -K  +  -ATPase activity in human placental villi. 
Presumably, other Na  +  -dependent aa transport systems would 
also be inhibited by enhanced AT  1   receptor activation.   Shibata 
et al.   (  2006  ) suggest that their fi  ndings may account for the 
adverse aff  ects of enhanced AT  1   receptor activation on fetal 
growth. They specifi  cally suggest that one possible source of 
excess AT  1   receptor activation in IUGR associated with 
preeclampsia is the presence of AT  1  -AAs in the maternal 
circulation. The research we report in this paper adds sup-
port to their speculation. 
  Other examples of IUGR, including fetal loss, involve 
the deleterious eff  ects of autoantibodies at the maternal–
fetal interface. One of the best-studied examples is that of 
patients with antiphospholipid syndrome, characterized by 
    Figure 7.     Schematic of the working model of AT  1   receptor–mediated apoptosis: placental and fetal consequences.   AT 1   receptor  activation 
via AT  1  -AAs, found in the serum of preeclamptic women, leads to (1) placental damage (2) and fetal abnormalities. sEng, soluble endoglin; sFlt-1, solu-
ble fms-like tyrosine kinase 1.     JEM VOL. 206, November 23, 2009 
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role of AT  1  -AAs in preeclampsia-associated IUGR and re-
vealed underlying mechanisms for this process. Selective 
neutralization of these autoantibodies would enhance our 
ability to intervene in IUGR without fetotoxicity, and sug-
gests that targeting AT  1  -AAs is a potentially important thera-
peutic strategy for the treatment of preeclampsia and its 
devastating clinical fetal complications. 
  MATERIALS AND METHODS 
  Patients.     Patients admitted to Memorial Hermann Hospital were identi-
fi  ed by the obstetrics faculty of the University of Texas Medical School at 
Houston Health Science Center. Patients were diagnosed with severe pre-
eclampsia based on the blood pressure criteria set by the   National High 
Blood Pressure Education Program Working Group   (  2000  ;   n   = 12). Inclu-
sion criteria were a blood pressure reading of 160 mmHg systolic or higher 
or 110 mmHg diastolic or higher in women who were normotensive be-
fore 20 wk gestation age (WGA). Blood pressure measurements were taken 
on two occasions at least 6 h apart. An absolute level of proteinuria measur-
ing 0.3 g of protein or higher in a 24-h urine specimen was another require-
ment for diagnosis. This value normally corresponds to ≥30 mg/dl (≥1 + 
reading on dipstick) in a random urine determination with no evidence of 
urinary tract infection. These women had no previous history of hyperten-
sion. The working group report does not strictly defi  ne early or late onset 
subclassifi  cations. However, our cohort of preeclamptic patients included 
women with symptom onset <30 WGA (  n   = 4) and those ≥30 WGA (  n   = 8). 
Preeclamptic sera were used as a source for AT  1  -AA, and similar concentra-
tions of the autoantibody were found in both groups. Control patients were 
normotensive pregnant individuals with uncomplicated pregnancies who 
were undergoing normal term deliveries (  n   = 12). The clinical characteris-
tics of the study patients are presented in   Table I  .   Blood samples were 
drawn, allowed to clot, and subsequently centrifuged at 18,000   g   at 4°C for 
10 min. Sera were collected and stored at     80°C. The research protocol, 
including the informed consent form, was approved by the University of 
Texas Health Science Center at Houston institutional Committee for the 
Protection of Human Subjects. 
  Reagents.     Cell-culture medium, antibiotics, and FBS were purchased from 
Invitrogen. Ang II was purchased from Sigma-Aldrich. Losartan was a gen-
erous gift from Merck & Co., Inc. A short 7-aa peptide corresponding to 
an epitope on the second extracellular loop of the human AT  1   receptor 
(AFHYESQ) was purchased from Baylor College of Medicine (Houston, TX). 
  Preparation of IgG fraction from patient sera.     IgG fractions were 
isolated from patient sera as previously described (  Zhou et al., 2008b  ) using 
  Losartan and the 7-aa epitope peptide were used to assess 
the specifi  city of the observed autoantibody-induced eff  ects. 
Coinjection of AT  1  -AAs with the AT  1   receptor blocker 
losartan resulted in diminished placental destruction and fetal 
abnormalities, indicating that eff  ects were mediated by auto-
antibody-induced AT  1   receptor activation. Consistent with 
the in vivo experiments, coincubation of losartan and AT  1  -AAs 
reduced apoptosis in the human villous explant and cell-culture 
systems. Similar fi  ndings were observed by coinjection of 
AT  1  -AAs and the 7-aa epitope peptide. It is unlikely that this 
peptide would be stable in the circulation of the injected 
mice if it were not in a complex with the autoantibody, which 
is why it is coinjected simultaneously. It will be necessary to 
synthesize stable derivatives of this peptide for use in preclini-
cal studies and potential clinical trials. More research is needed 
to exploit the therapeutic potential suggested by the result of 
our peptide-blocking experiments. Collectively, the ability 
of losartan and 7-aa epitope peptide to reduce harmful auto-
antibody eff  ects provide additional evidence that AT  1  -AAs 
contribute to the IUGR and placental impairment associated 
with preeclampsia. More importantly, the ability of the 7-aa 
epitope peptide to neutralize the eff  ects of AT  1  -AAs repre-
sents a potential therapeutic approach to block the autoanti-
body-mediated AT  1   receptor activation seen in preeclampsia 
and the associated IUGR. 
  In conclusion, our study demonstrates that AT  1  -AAs may 
contribute to IUGR through a direct detrimental eff  ect by 
activation of AT  1   receptors on multiple fetal organs, and in-
directly by inducing small placentas characterized by increased 
trophoblast apoptosis (  Fig. 7  ).   Future work will have to de-
lineate between the placental eff  ects and the direct harmful 
action of the autoantibody on the fetus. However, there is no 
doubt that our studies identify AT  1  -AA as a detrimental fac-
tor that contributes to IUGR. Furthermore, we have shown 
that the blockade of excessive AT  1   receptor stimulation by 
losartan or the 7-aa epitope peptide not only reduced the 
placental apoptosis observed in mouse and human placentas 
but also the fetal abnormalities seen in the autoantibody-
injected mouse model. Thus, our work identifi  ed the detrimental 
    Table I.    Clinical characteristics of patients 
Normotensive (  n   = 12) Preeclamptic (  n   = 12)
Maternal age (yr) 24 ± 4.71 28.42 ± 6.13
Gestation age (wk) 38.63 ± 0.98 31.21 ± 2.8
Primigravid (%) 33 25
Systolic blood pressure (mmHg) 118.2 ± 4.97 181.3 ± 16.93*
Diastolic blood pressure (mmHg) 67.33 ± 6.21 106.8 ± 13.22*
Proteinuria (mg/24 h) <300 554.5 ± 800.7
Fetal weight (g) 3,347 ± 429 1,437 ± 390
Weight by gestational age (percentile) 58.1 ± 31 20.2 ± 18*
Number of babies born at <10th percentile (  n   [%]) 1 (8%) 6 (50%)*
Luciferase activity of patient serum (fold induction) 1.64 ± 0.97 7.68 ± 0.34*
This table illustrates the key differences between the two patient populations used in the experiments. The preeclamptic women demonstrate increased blood pressure, 
proteinuria, and luciferase activity, which refl  ects the biological activity of AT  1  -AA. 6 out of the 12 babies (50%) born to the preeclamptic cohort weighed <10th percentile for 
their gestational age, whereas only 1 out of 12 of babies (8%) born to the normotensive cohort were considered IUGR. *, P < 0.05.2820 AT  1  -AA in IUGR   | Irani et al. 
bital i.p., and 20 μg of affi   nity-purifi  ed IgG was introduced into pregnant mice 
via orbital sinus injection at E13 and again on E14. We chose E13 because this 
stage of mouse pregnancy is comparable to early onset preeclampsia in humans 
and is a time at which we can reliably determine if a mouse is pregnant. 
In some cases, the autoantibody was simultaneously coinjected with either 
8 mg/kg losartan i.v. or 50 mg/kg of the 7-aa epitope peptide i.v. Mouse sys-
tolic blood pressure was measured by tail cuff   (AD Instruments). The dams 
were sacrifi  ced at E18 when fetal mouse organs and blood (which was pooled 
from the same littermates) were collected. Only fetuses born in litters of six to 
eight pups were analyzed in fetal mouse experiments. All animal studies were 
reviewed and approved by the Animal Welfare Committee of the University 
of Texas Health Science Center at Houston. 
  Western blotting.     The presence of AT  1  -AAs in human serum was ana-
lyzed by Western blotting as previously described (  Zhou et al., 2008b  ). In 
brief, 30 μg/well of proteins from CHO-NFAT cells stably transfected with 
the AT  1   receptor gene were run on 10% SDS-PAGE gel and transferred to 
a nitrocellulose membrane. The membrane was cut to strips and blocked. 
The strips were probed with purifi  ed human IgG (1:10 dilution) and mouse 
anti–human IgG conjugated with horseradish peroxidase (1:5,000 dilution; 
Jackson ImmunoResearch Laboratories). One strip was probed with anti-
AT  1   receptor antibody (1:1,000 dilution; Santa Cruz Biotechnology, Inc.) 
and goat anti–rabbit IgG conjugated with horseradish peroxidase (1:5,000 
dilution; Jackson ImmunoResearch Laboratories) as positive controls. 
Human IgG in fetal mouse circulation was also analyzed by Western blotting. 
12 μl of fetal mouse serum was run on 10% SDS-PAGE gel and transferred 
to a nitrocellulose membrane. The membrane was probed with mouse anti–
human IgG antibody. For the assessment of apoptotic markers in mouse and 
human placentas, rabbit anti–human or anti–mouse primary antibodies 
against Bax, a 23-kD proapoptotic protein, and Bcl-2, a 26-kD antiapoptotic 
protein, were used in a 1:200 dilution (Santa Cruz Biotechnology, Inc.). 
    -Actin, a 43-kD housekeeping gene, was used as a loading control (Santa 
Cruz Biotechnology, Inc.). Relative densiometry was assessed using the 
Storm 840 Phosphorimager and the accompanying ImageQuant TL analysis 
software (both from GE Healthcare). All signals of Western blotting were 
detected by the ECL kit (GE Healthcare). 
  ELISA.     For determination of human IgG concentration in fetal mouse cir-
culation, fetal mouse serum was diluted 300-fold, and the concentration 
of human IgG in the serum was quantifi  ed by a commercial ELISA kit 
(Thermo Fisher Scientifi  c). 
  Human placental explants.     Human placentas were obtained from normo-
tensive pregnant patients whose pregnancies were uncomplicated and under-
went an elective term Caesarean section at Memorial Hermann Hospital. The 
culture system described was adapted from   Ahmad and Ahmed   (  2004  ). Upon 
delivery, the placentas were placed on ice and submerged in phenol red–free 
DMEM containing 0.2% BSA and 1% antibiotics. Within 30 min of delivery, 
chorionic villous explant fragments were carefully dissected from the placenta 
and transferred to 24-well plates for an overnight equilibration period at 37°C. 
The explants were incubated with saline, 100 nM Ang II, or IgG from either 
preeclamptic or normotensive pregnant women (1:10 dilution). Some experi-
ments involved the coincubation of IgG with 5 μM losartan or 1 μM of the 
7-aa blocking epitope peptide, which was added to the serum-free culture 
medium at the same time as the human IgG. After 24 h, the media was si-
phoned and stored at     80°C, and the villous explants were either lysed for use 
in Western blot analysis or fi  xed in 10% formalin for embedding in paraffi   n 
wax and further histological or immunohistochemical analysis. 
  Human trophoblast cell culture.     To assess the level of AT  1   receptor–medi-
ated apoptosis, HTR-8/SVneo cells, an immortalized human trophoblast cell 
line (  Graham et al., 1993  ), were plated at 2 × 10  4   cells per well in 8-well cham-
ber slides overnight (Laboratory-Tek; Thermo Fisher Scientifi  c). The next 
day, serum-free media was used and cells were incubated with 100 nM Ang II 
or IgG from either preeclamptic or normotensive pregnant women (1:10 dilu-
tion) and cultured for an additional day. For some experiments, 5 μM losartan 
GammaBind G Sepharose (GE Healthcare). Typically, 200 μl of patient sera 
was applied to the column matrix and eluted in 1.8 ml of buff  er according to 
the manufacturer’s recommended protocol. The isolated IgG was assayed for 
the presence of AT  1  -AA using the luciferase reporter cell line described in 
Bioassay to determine the presence of AT  1  -AA. According to this assay, 
nearly all of the women with severe preeclampsia (25 out of 26) harbored 
AT  1  -AAs, whereas less than one third of the normotensive pregnant women 
possessed AT  1  -AAs, and in these women the autoantibody concentration 
was signifi  cantly reduced (  Siddiqui et al., In press  ). IgG fractions from indi-
vidual patients were used separately for the experiments reported in this pa-
per. Individual patient IgG preparations were not pooled. 
  Affi   nity purifi  cation of AT  1  -AA from human IgG.     The ability of the 
7-aa epitope peptide to block autoantibody-induced receptor activation sug-
gests a physical association between the autoantibodies and AT  1   receptors. 
We took advantage of this presumed physical association as the basis of 
an affi   nity purifi  cation strategy to obtain highly enriched preparations of 
AT  1  -AAs. For this purpose, we prepared a glutathione   S  -transferase (GST) 
fusion protein containing a 27-aa peptide encoding the entire second extra-
cellular loop of the AT  1   receptor. The construction and expression of the 
GST-27mer AT  1   receptor fusion protein and its subsequent use in AT  1  -AA 
affi   nity  purifi  cation was performed as previously described (  Zhou et al., 
2008b  ). In brief, a pGEX-4T-1 GST expression vector (Promega) contain-
ing the GST-27mer-AT  1   receptor fusion protein encoding 27 aa’s corre-
sponding to the second extracellular loop of the human AT  1   receptor 
(available from GenBank/EMBL/DDBJ under accession no.  NM_009585.2  ) 
was used to transform BL21 DE3   Escherichia coli   cells (Stratagene). After in-
duction and collection of cells, the GST-27mer-AT  1   receptor fusion protein 
was isolated by glutathione beads (GE Healthcare) and its expression was 
confi  rmed by Western blotting. The GST-27mer AT  1   receptor fusion pro-
tein was then linked to agarose beads by a microlink protein coupling kit 
(Thermo Fisher Scientifi  c) according the manufacturer’s protocol and used 
in an affi   nity chromatography column. Total IgG isolated from preeclamptic 
or normotensive patient sera was loaded on the affi   nity chromatography col-
umn and incubated for 3 h at room temperature. The fl  ow-through fraction 
was collected and the bound IgG (AT  1  -AA) was then eluted by centrifuga-
tion. The affi   nity of AT  1  -AA for the GST-27mer–AT  1   receptor fusion pro-
tein was exploited in an affi   nity purifi  cation scheme resulting in a 40-fold 
enrichment of AT  1  -AA in the eluted fraction. Only the eluted fraction 
(affi   nity-purifi  ed AT  1  -AA) was able to bind to AT  1   receptors transferred to 
a nitrocellulose membrane. In contrast, the affi   nity chromatography fl  ow-
through fraction could not bind to the 43-kD AT  1   receptor and was not 
detected by Western blot analysis. To confi  rm which fraction retained bio-
logical activity, we used an established luciferase activity assay. Only the pre-
eclamptic eluted fraction (containing AT  1  -AAs) could stimulate luciferase 
activity, whereas the other fractions could not. This fraction was used in the 
subsequent experimentation. 
  Bioassay to determine the presence of AT  1  -AA.     Chinese hamster ovary 
(CHO) cells stably transfected with rat Ang II receptor type 1A (CHO.AT1A) 
were provided by T.S. Elton (The Ohio State University, Columbus, OH). 
Cells were maintained and cultured in RPMI 1640 medium containing 5% FBS, 
1% antibiotics, 8.75 g/liter proline and 100 μg/ml gentamycin and hygromycin 
at 37°C and 5% CO  2  . Cells were stably transfected with an NFAT-luciferase re-
porter construct containing four copies of the NFAT binding element driving 
the expression of a luciferase reporter gene. 10  5   CHO.AT1A cells containing 
stably integrated copies of a minigene encoding the rat AT  1   receptor and a 4× 
NFAT-driven luciferase construct were plated on 24-well plates overnight. The 
next day, cells were changed to serum-free medium and treated with IgG (1:10 
dilution) for 24 h. The treated cells were lysed in 100 μl of passive lysis buff  er 
(Promega) at room temperature for 45 min. Luciferase activity (measured in rela-
tive light units) was assessed using 20 μl of lysate with a Dual-Luciferase Reporter 
Assay System (Promega) according to the manufacturer’s protocol. 
  Introduction of antibody into mice.     C57BL/6J pregnant mice (18–22 g; 
Harlan) were used. Mice were anesthetized with 50 mg/kg sodium pentobar-JEM VOL. 206, November 23, 2009 
Article
2821
      Alexander  ,   G.R.  ,   M.     Kogan  ,   D.     Bader  ,   W.     Carlo  ,   M.     Allen  , and   J.     Mor  . 
  2003  .   US birth weight/gestational age-specifi  c  neonatal  mortality: 
1995-1997 rates for whites, hispanics, and blacks.       Pediatrics      .     111  :  e61  –  e66  . 
  doi:10.1542/peds.111.1.e61     
      Allaire  ,   A.D.  ,   K.A.     Ballenger  ,   S.R.     Wells  ,   M.J.     McMahon  , and   B.A.     Lessey  . 
  2000  .   Placental apoptosis in preeclampsia.       Obstet. Gynecol.       96  :  271  –  276  . 
  doi:10.1016/S0029-7844(00)00895-4     
      Barker  ,   D.J.     1998  .   In utero programming of chronic disease.       Clin. Sci. 
(Lond.)      .     95  :  115  –  128  .   doi:10.1042/CS19980019     
      Bauer  ,   M.K.  ,   J.E.     Harding  ,   N.S.     Bassett  ,   B.H.     Breier  ,   M.H.     Oliver  ,   B.H.   
  Gallaher  ,   P.C.     Evans  ,   S.M.     Woodall  , and   P.D.     Gluckman  .   1998  .   Fetal 
growth and placental function.       Mol. Cell. Endocrinol.       140  :  115  –  120  . 
  doi:10.1016/S0303-7207(98)00039-2     
      Baum  ,   M.  ,   L.     Ortiz  , and   A.     Quan  .   2003  .   Fetal origins of cardiovascular 
disease.       Curr. Opin. Pediatr.       15  :  166  –  170  .   doi:10.1097/00008480-
200304000-00005     
      Bobst  ,   S.M.  ,   M.C.     Day  ,   L.C.     Gilstrap     III  ,   Y.     Xia  , and   R.E.     Kellems  .   2005  . 
  Maternal autoantibodies from preeclamptic patients activate angiotensin 
receptors on human mesangial cells and induce interleukin-6 and plas-
minogen activator inhibitor-1 secretion.       Am. J. Hypertens.       18  :  330  –  336  . 
  doi:10.1016/j.amjhyper.2004.10.002     
      Cetin  ,   I.  , and   G.     Alvino  .   2009  .   Intrauterine growth restriction: implications 
for placental metabolism and transport. A review.       Placenta      .     30  (  Suppl. 
A  ):  S77  –  S82  .   
      Cetin  ,   I.  ,   J.M.     Foidart  ,   M.     Miozzo  ,   T.     Raun  ,   T.     Jansson  ,   V.     Tsatsaris  , 
  W.     Reik  ,   J.     Cross  ,   S.     Hauguel-de-Mouzon  ,   N.     Illsley  ,   et al  .   2004  . 
  Fetal growth restriction: a workshop report.       Placenta      .     25  :  753  –  757  . 
  doi:10.1016/j.placenta.2004.02.004     
      Chistiakov  ,  D.A.    2003  .  Thyroid-stimulating hormone receptor and its role in 
Graves’ disease.       Mol. Genet. Metab.       80  :  377  –  388  .   doi:10.1016/j.ymgme
.2003.09.001     
      Deleze  ,   M.  ,   D.     Alarcón-Segovia  ,   E.     Valdes-Macho  ,   C.V.     Oria  , and   S.     Ponce 
de Leon  .   1989  .   Relationship between antiphospholipid antibodies and 
recurrent fetal loss in patients with systemic lupus erythematosus and 
apparently healthy women.       J. Rheumatol.       16  :  768  –  772  .   
      DiFederico  ,   E.  ,   O.     Genbacev  , and   S.J.     Fisher  .   1999  .   Preeclampsia is associ-
ated with widespread apoptosis of placental cytotrophoblasts within the 
uterine wall.       Am. J. Pathol.       155  :  293  –  301  .   
      Georgiades  ,   P.  ,   A.C.     Ferguson-Smith  , and   G.J.     Burton  .   2002  .   Comparative 
developmental anatomy of the murine and human defi  nitive placentae.   
    Placenta      .     23  :  3  –  19  .   doi:10.1053/plac.2001.0738     
      Girardi  ,   G.  ,   J.     Berman  ,   P.     Redecha  ,   L.     Spruce  ,   J.M.     Thurman  ,   D.     Kraus  , 
  T.J.     Hollmann  ,   P.     Casali  ,   M.C.     Caroll  ,   R.A.     Wetsel  ,   et al  .   2003  . 
  Complement C5a receptors and neutrophils mediate fetal injury in the 
antiphospholipid syndrome.       J. Clin. Invest.       112  :  1644  –  1654  .   
      Godfrey  ,   K.M.  , and   D.J.     Barker  .   2000  .   Fetal nutrition and adult disease.       Am. 
J. Clin. Nutr.       71  (  Suppl.  ):  1344S  –  1352S  .   
      Graham  ,   C.H.  ,   T.S.     Hawley  ,   R.G.     Hawley  ,   J.R.     MacDougall  ,   R.S.     Kerbel  , 
  N.     Khoo  , and   P.K.     Lala  .   1993  .   Establishment and characterization of 
fi  rst trimester human trophoblast cells with extended lifespan.       Exp. Cell 
Res.       206  :  204  –  211  .   doi:10.1006/excr.1993.1139     
      Hales  ,   C.N.  , and   S.E.     Ozanne  .   2003  .   For debate: Fetal and early postnatal 
growth restriction lead to diabetes, the metabolic syndrome and renal 
failure.       Diabetologia      .     46  :  1013  –  1019  .   doi:10.1007/s00125-003-1131-7     
      Holers  ,  V.M.  ,  G.    Girardi  ,  L.    Mo  ,  J.M.    Guthridge  ,  H.    Molina  ,  S.S.    Pierangeli  ,  R.   
  Espinola  ,   L.E.     Xiaowei  ,   D.     Mao  ,   C.G.     Vialpando  , and   J.E.     Salmon  .   2002  . 
  Complement C3 activation is required for anti  phospholipid antibody-   
induced fetal loss.       J. Exp. Med.       195  :  211  –  220  .   doi:10.1084/jem.200116116     
      Huppertz  ,   B.  , and   J.C.     Kingdom  .   2004  .   Apoptosis in the trophoblast—
role of apoptosis in placental morphogenesis.       J. Soc. Gynecol. Investig.     
  11  :  353  –  362  .   doi:10.1016/j.jsgi.2004.06.002     
      Huppertz  ,   B.  ,   M.     Kadyrov  , and   J.C.     Kingdom  .   2006  .   Apoptosis and its role 
in the trophoblast.       Am. J. Obstet. Gynecol.       195  :  29  –  39  .   doi:10.1016/j.ajog
.2005.07.039     
      Irani  ,   R.A.  , and   Y.     Xia  .   2008  .   The functional role of the renin-angiotensin sys-
tem in pregnancy and preeclampsia.       Placenta      .     29  :  763  –  771  .   doi:10.1016/
j.placenta.2008.06.011     
      Johansson  ,   M.  ,   T.     Jansson  , and   T.L.     Powell  .   2000  .   Na(+)-K(+)-ATPase is 
distributed to microvillous and basal membrane of the syncytiotrophoblast 
or 1 μM of the 7-aa epitope peptide was added to the chamber well at the same 
time as the human IgG. The next day, cells were either lysed for caspase 3 ac-
tivity analysis or permanently fi  xed to the slide for subsequent staining. 
  TUNEL assay and index.     HTR-8/SVneo cells manipulated as described 
in the previous section or 4-μm sections of mouse or human placental tissue 
collected from the experiments described earlier were permanently fi  xed 
onto a glass slide, deparaffi   nized, and rehydrated through an alcohol gradient 
by standard techniques. Cells or tissue were permeabilized using cold, fresh 
0.1% Triton X-100 in 0.1% sodium citrate and stained by TUNEL using a 
commercial kit (Roche) according to the manufacturer’s protocol. TUNEL-
positive cells are identifi  ed by cellular morphology (cell shrinkage, mem-
brane blebbing, and nuclear fragmentation) and positive green staining under 
515–565 nm of fl  uorescent light. Negative control sections were treated in a 
similar fashion but lacking the terminal deoxynucleotidyl transferase enzyme. 
To identify healthy cells with normal nuclear morphology, after TUNEL 
staining was complete a DAPI nuclear stain was added and visualized as blue 
when excited at 360 nm of fl  uorescent light (Vector Laboratories). For each 
TUNEL and DAPI-stained cell or tissue section, green apoptotic and blue 
healthy nuclei were blindly counted in 10 random microscopic fi  elds. Quan-
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nuclei × 100) was assessed blindly in 10 random microscopic fi  elds per sam-
ple using Image Pro Plus 6.3 software (Media Cybernetics). 
  Caspase 3 activity assay.     To measure the activity of caspase 3, a sensitive 
commercial assay was used (Millipore). HTR-8/SVneo cells were cultured as 
described. 0.5 × 10  6   cells were pelleted and lysed to obtain the cytosolic ex-
tract, on which the activity assay was performed according to the manufactur-
er’s protocol. Relative absorbance was measured on a spectrophotometer at a 
wavelength of 405 nm, which correlates to the caspase 3 activity level. 
  Histological analysis.     The kidneys and livers of fetal mice were harvested 
and fi  xed in a zinc solution (BD). The tissues were processed according 
to standard protocols. In brief, the tissues were fi  xed in a zinc solution for 
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dehydrated, infi  ltrated, and embedded in paraffi   n. 4-μm serial sections were 
obtained and stained with hematoxylin and eosin (H&E) by standard tech-
niques. The number of glomeruli in the fetal kidney samples was assessed 
blindly by counting and averaging the number of glomeruli in 10 random 
high power microscopic fi  elds per sample. 
  Statistical analysis.     All data are expressed as means ± SEM. Data were ana-
lyzed for statistical signifi  cance using Prism 4 software (GraphPad Software, 
Inc.). Student’s   t   tests (paired or unpaired as appropriate) were applied in a 
two-group analysis. Diff  erences between the means of multiple groups were 
compared by the one-way analysis of variance, followed by a Tukey’s multi-
ple comparisons test. P < 0.05 was considered signifi  cant and was the thresh-
old to reject the null hypothesis. 
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